![]() ![]() The "entire impact" of the COVID-19 decline was within the diagnostics business, and the company expects the COVID-19 impact to get smaller over the course of 2023 and the overall impact to disappear completely by the end of Q1 2024, he added. Schinecker noted on the call that the COVID-19 sales decline was in line with the guidance Roche provided at the beginning of 2023. Schinecker said in a statement that "sales in the base business of both our divisions grew strongly, largely offsetting the impact of declining demand for COVID-19 products."ĬOVID-19 test sales in the period were CHF 400 million, down from CHF 3.1 billion in the first half of 2022. The diagnostics base business saw growth of CHF 421 million, Roche CEO Thomas Schinecker said on a conference call to discuss the firms results. ![]() Revenues for the Diagnostics division cam e in at CHF 7.10 billion, down 29 percent (and 23 percent at constant exchange rates) compared to CHF 9.95 billion in revenues during the same period last year. The firm's base business excluding COVID-19 product sales grew 8 percent at constant exchange rates. At constant exchange rates the decline was 2 percent. The company also emphasized the importance of recent and upcoming diagnostics product launches that will broaden its portfolio and continue to boost its base business.įor the first half of 2023, the Roche Group reported CHF 29.78 billion ($34.75 billion) in total sales, down 8 percent from CHF 32.30 billion during the first half of 2022. However, excluding those products, its base Dx business saw 6 percent growth at constant exchange rates, driven by growth in immunodiagnostics and clinical chemistry. NEW YORK – Roche on Thu rsday reported its Diagnostics division revenues fell 29 percent year over year in the first half of 2023 as a result of expected lower demand for COVID-19 tests. Note: This story has been updated with comments from the company's conference call to discuss its financial results. Advances in Clinical Genomics Profiling.To learn more about other genetic testing, visit the Genetics Division Website. This new type of prenatal screening is a maternal blood test that uses cell-free DNA to assess the risk that a baby will be born with certain genetic abnormalities. ![]() ![]() Learn More Non-invasive prenatal screening The ColoSeq TM panel is a comprehensive genetic test for hereditary colon cancer that includes genes known to causes diseases such as Lynch Syndrome. This test sequences several different genes known to increase cancer risk, including BRCA1 and BRCA2. The BROCA TM panel was one of the firsts tests available to determine if a patient has an increased risk of getting cancer due to a genetic alteration. Learn More Cancer Risk Panels: BROCA and ColoSeq More than 350 genes related to cancer treatment, prognosis, risk, and diagnosis are tested. The test uses next-generation “deep” sequencing of a patient’s tumor to detect characteristic genetic changes. UW-OncoPlex TM is a cancer profiling test developed by UW faculty in the Department of Laboratory Medicine and Pathology. The genetics and solid tumor lab offer DNA-based testing for a variety of different genetic disorders. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |